At the 96th Annual Meeting of Japanese Gastric Cancer Association, an interim report on the Phase Ⅰ/Ⅱ trial of intraperitoneal infusion of GAIA-102 for gastric/pancreatic cancer will be presented.

Fukuoka, JAPAN – Dr. Eiji OKI, MD PhD, the Department of Surgery and Science at Kyushu University Hospital, will present an interim report of Phase I/Ⅱ trial of intraperitoneal infusion of GAIA-102 for gastric/pancreatic cancer at the 96th Annual Meeting of Japanese Gastric Cancer Association.

Presentation at the Annual Meeting:

Session: International Session 4 Treatment Strategy of Stage 4 Gastric Cancer
Scheduled for: March 1, 2024 (Friday) 8:20~9:50 (JST), Room 9, Miyako Messe Exhibition Center, Kyoto

About the Study:

This Phase I/Ⅱ clinical study aims to gauge both the safety and clinical efficacy of GAIA-102. The study has been registered under ClinicalTrials.gov ID: NCT05438459.
Dr. Eiji OKI is the principal investigator of this study.

Funding & Support:

This crucial study has received financial backing from the Japan Agency for Medical Research and Development (AMED). Additionally, GAIA BioMedicine Inc. has generously provided the test drug.

About GAIA BioMedicine:

GAIA BioMedicine, Inc., founded in 2015 by Prof. Yoshikazu YONEMITSU, MD PhD, as a spin-off venture of Kyushu University, is a clinical-stage and technology-driven biopharmaceutical company specializing in cell therapies for cancer using NK cells.

https://www.congre.co.jp/96jgca2024/index.html

Share on